Updated:
Adicet Bio
Adicet Bio is a clinical-stage biotech led by CEO Chen Schor, developing off-the-shelf gamma delta T-cell therapies for cancer.
Adicet Bio
Adicet Bio was founded in 2014 and operates from Boston, Massachusetts, and Redwood City, California, under CEO Chen Schor. The company emerged from the convergence of advances in T-cell biology and a growing appetite for allogeneic, or donor-derived, cell therapies that bypass the logistical and manufacturing bottlenecks of autologous CAR-T. Rather than the bespoke, vein-to-vein model employed by pioneers like Novartis and Gilead's Kite Pharma, Adicet's platform starts with healthy donor cells to produce an off-the-shelf product. The firm's pipeline is built on gamma delta T cells, a distinct lymphocyte lineage that combines innate and adaptive immune functions. Its lead candidate, ADI-001, targets CD20 for relapsed or refractory B-cell non-Hodgkin lymphoma and has generated clinical data since 2021. A second program, ADI-270, targets CD70-positive renal cell carcinoma, marking the company's expansion into solid tumors. Adicet pairs CAR engineering with an additional chimeric adaptor protein arm to enhance tumor-killing and persistence. The platform aims to serve multiple oncology indications across hematologic and solid tumor settings through a single manufacturing process. Adicet Bio trades on Nasdaq under the ticker ADCT. The firm has reported cash and cash equivalents sufficient to fund operations into 2026, reflecting the capital demands of clinical-stage biotechnology. In July 2024, the company presented updated Phase 1 data for ADI-001 at the European Hematology Association Congress, highlighting durable responses in heavily pre-treated lymphoma patients (per Adicet Bio's July 2024 corporate presentation). Its Redwood City facility supports process development and manufacturing for both clinical and eventual commercial supply. The company's structural differentiator lies in its gamma delta T-cell chassis. Unlike alpha beta CAR-T therapies, gamma delta cells recognize tumor targets through both their engineered CAR and their native cytotoxic receptors, potentially reducing the risk of antigen escape — a common failure mode in CAR-T treatment. This dual-targeting architecture, combined with an allogeneic manufacturing model, positions Adicet to pursue a product profile that is both scalable and mechanistically distinct from the first generation of cell therapies.
General information
Firm type
Asset Manager
Year founded
2014
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Additional offices
Redwood City, CA, United States
Principals
Chen Schor
President and Chief Executive Officer
Sector focus
Frequently asked questions
How does Adicet Bio's technology differ from traditional CAR-T therapies?
Adicet Bio uses gamma delta T cells instead of the alpha beta T cells in conventional CAR-T products. Gamma delta cells naturally bridge innate and adaptive immunity, retaining the ability to kill tumor cells through their native receptors even if the engineered CAR target is lost. Additionally, Adicet's cells come from healthy donors, creating an off-the-shelf product that eliminates the weeks-long, patient-specific manufacturing required for autologous CAR-T therapies.
What is Adicet Bio's lead clinical program?
The lead program is ADI-001, an allogeneic gamma delta CAR-T therapy targeting CD20. It is in Phase 1 development for relapsed or refractory B-cell non-Hodgkin lymphoma. The company has reported clinical proof-of-concept data, including durable responses in heavily pre-treated patients, and is advancing toward later-stage trials.
Does Adicet Bio target solid tumors as well as blood cancers?
Yes. ADI-270 is an allogeneic gamma delta CAR-T therapy targeting CD70 in renal cell carcinoma, and it represents the company's expansion into solid tumors. The platform's dual innate and engineered targeting is designed to address the immunosuppressive tumor microenvironment that often defeats other cell therapies.
Who leads the investment and strategic decisions at Adicet Bio?
Chen Schor, President and CEO, leads the company's overall strategy and operations. Major capital allocation, partnership, and pipeline decisions are made by the executive team under the oversight of a board of directors that includes representatives from significant institutional investors such as OrbiMed and venBio.
How is Adicet Bio capitalized, and what is its cash runway?
Adicet Bio is a publicly traded company on Nasdaq. In its most recent filings, the company has reported cash and equivalents expected to fund operations into 2026, based on current operating plans and clinical development timelines. Like all clinical-stage biotechs, future financing will depend on data readouts and market conditions.
What is Adicet Bio's manufacturing model?
Adicet manufactures its therapies at its own facility in Redwood City, California. The process starts with leukapheresis material from healthy donors, which is then engineered and expanded into a cryopreserved, off-the-shelf dose. This internal, centralized manufacturing is designed to produce hundreds of patient doses from a single donor collection, a fundamentally different cost structure from patient-scale autologous CAR-T production.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: